3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
23
Breast Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
7
Fallopian Tube Neoplasms
7
Stomach Neoplasms
5
Neoplasm Metastasis
5
Sarcoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Metastatic Castration-resistant Prostate Cancer
4
Fanconi Anemia, Complementation Group D1
4
Small Cell Lung Carcinoma
3
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Endometrial Neoplasms
2
Interventions
olaparib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumor, Adult
×
olaparib
×
Clear all
NCT04972110
2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2
Terminated
156 enrolled
19 charts